6/29/23, 1:34 AM PARTNER A Pathway Feedback Search Clinical Topics Home Studies PARTNER A PARTNER A Disease Aortic stenosis Trial question Is TAVR noninferior to SAVR in high-risk patients with severe aortic stenosis? Study design Multi-center Open label RCT Population Characteristics of study participants 43.0% female N = 699 57.0% male 699 patients (298 female, 399 male) Inclusion criteria: high-risk patients with severe aortic stenosis Key exclusion criteria: bicuspid or noncalcified valve, coronary artery disease requiring revascularization, LVEF < 20%, an aortic annulus diameter < 18 mm or > 25 mm, severe mitral or AR, recent neurologic event, and severe renal insufficiency Interventions N=348 TAVR (with a balloon-expandable bovine pericardial valve, either a transfemoral or a transapical approach) N=351 surgical AVR (surgical aortic-valve replacement) Primary outcome https://web.pathway.md/studies/rectjsOuwhfWTUJaZ 1/2 6/29/23, 1:34 AM PARTNER A Pathway Death at 1 year 26.8 % 26.8 24.2 20.1 % 13.4 % Difference not exceeding nonferiority margin 6.7 % 0.0 % Transcatheter aortic valve replacement Surgical AVR Difference not exceeding nonferiority margin in death at 1 year (24.2% vs. 26.8%; MD -2.6, 95% CI -9.3 to 4.1) Secondary outcomes Significant increase in major vascular complications, at 30 days (11% vs. 3.2%; ARD 7.8, 95% CI 3.17 to 12.43) Safety outcomes Significant differences in at 30 days, major bleeding (9.3% vs. 19.5%, p < 0.001) and new-onset AF (8.6% vs. 16.0%, p = 0.006). Conclusion In high-risk patients with severe aortic stenosis, TAVR was noninferior to surgical AVR with respect to death at 1 year. Reference Smith CR, Leon MB, Mack MJ et al. Transcatheter versus surgical aortic-valve replacement in high- risk patients. N Engl J Med. 2011 Jun 9;364(23):2187-98. Open reference URL https://web.pathway.md/studies/rectjsOuwhfWTUJaZ 2/2